Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Sponsor: Xencor, Inc.
Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.
Official title: A Phase 1 Trial, Evaluating the Safety and Tolerability of XmAb541 in Combination With XmAb808 in Advanced Solid Tumors
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-06
Completion Date
2028-12
Last Updated
2026-05-18
Healthy Volunteers
No
Conditions
Interventions
XmAb541
Monoclonal Bispecific Antibody
XmAb808
Monoclonal Bispecific Antibody
Locations (9)
Xencor Investigative Site
Detroit, Michigan, United States
Xencor Investigative Site
Omaha, Nebraska, United States
Xencor Investigative Site
Lake Success, New York, United States
Xencor Investigative Site
New York, New York, United States
Xencor Investigative Site
The Bronx, New York, United States
Xencor Investigative Site
Columbus, Ohio, United States
Xencor Investigative Site
Oklahoma City, Oklahoma, United States
Xencor Investigative Site
Fort Worth, Texas, United States
Xencor Investigative Site
Houston, Texas, United States